Ascil Biopharm

Phase 1

Cerdanyola del Valles, SpainFounded 2019ascil-biopharm.com

Ascil Biopharm is a Barcelona-based biotech company with a dual business model: developing its own innovative drug delivery systems and providing contract development and manufacturing (CDMO) services. The company specializes in complex formulations for systemic and locoregional delivery, with a clinical-stage pipeline and a portfolio of proprietary medical devices. Its strategy leverages European grant funding and aims to address unmet medical needs through enhanced drug efficacy, safety, and patient convenience.

Founded

2019

Focus

Drug Delivery

AI Company Overview

Technology Platform

Ascil Biopharm's core platform combines proprietary controlled-release formulations for systemic and locoregional delivery with precision-engineered medical devices for injectable administration, all supported by integrated GMP manufacturing capabilities.

Funding History

Total raised: $1.8M

Seed$1.8MUndisclosedSep 15, 2022

Opportunities

Ascil has significant growth opportunities in partnering its lead clinical program (APOC/AQUE) with a larger oncology-focused pharma company and in expanding its CDMO services for complex injectables across Europe.

Its novel device platforms, like DuoLapse for combination therapies, also present licensing opportunities in the burgeoning biologics and combination drug market.

Risk Factors

Key risks include clinical failure of its Phase 1 somatostatin analog program, reliance on grant funding and CDMO revenue for financial sustainability, and intense competition in both the drug delivery and contract manufacturing spaces from larger, better-capitalized players.

Competitive Landscape

Ascil competes with established somatostatin analog marketers (Novartis, Ipsen) on formulation innovation and with global CDMOs (Lonza, Catalent) on niche expertise in complex parenteral delivery. Its differentiation lies in the integrated combination of novel formulations with proprietary, patient-centric injection devices.